Literature DB >> 619907

Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques.

R G Stoller, C E Myers, B A Chabner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 619907     DOI： 10.1016/0006-2952(78)90256-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  10 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 2.  Clinical management of cytotoxic drug overdose.

Authors:  L L Thomas; M J Mertens; A E von dem Borne; C J van Boxtel; C H Veenhof; E P Veies
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

3.  Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.

Authors:  Duoli Guo; Paul B Myrdal; Kelly L Karlage; Sean P O'Connell; Travis J Wissinger; S Esmail Tabibi; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2010-02-12       Impact factor: 3.246

4.  Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-11-15       Impact factor: 3.333

5.  Cytosine arabinoside triphosphate production in human leukaemic myeloblasts: interactions with deoxycytidine.

Authors:  A L Harris; D G Grahame-Smith
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.

Authors:  Naotake Funamizu; Curtis Ray Lacy; Kaori Fujita; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga; Yoshinobu Manome
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

7.  Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA.

Authors:  Simon Gemble; Akshay Ahuja; Géraldine Buhagiar-Labarchède; Rosine Onclercq-Delic; Julien Dairou; Denis S F Biard; Sarah Lambert; Massimo Lopes; Mounira Amor-Guéret
Journal:  PLoS Genet       Date:  2015-07-16       Impact factor: 5.917

8.  Zebularine upregulates expression of CYP genes through inhibition of DNMT1 and PKR in HepG2 cells.

Authors:  Kazuaki Nakamura; Kazuko Aizawa; Kyaw Htet Aung; Junji Yamauchi; Akito Tanoue
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

9.  A role for Tau protein in maintaining ribosomal DNA stability and cytidine deaminase-deficient cell survival.

Authors:  Elias Bou Samra; Géraldine Buhagiar-Labarchède; Christelle Machon; Jérôme Guitton; Rosine Onclercq-Delic; Michael R Green; Olivier Alibert; Claude Gazin; Xavier Veaute; Mounira Amor-Guéret
Journal:  Nat Commun       Date:  2017-09-25       Impact factor: 14.919

10.  MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism.

Authors:  Appolinaire A Olou; Ryan J King; Fang Yu; Pankaj K Singh
Journal:  Oncogene       Date:  2020-02-26       Impact factor: 9.867
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.